scholarly journals A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis

2020 ◽  
Author(s):  
Cihan Heybeli ◽  
Andrew Bentall ◽  
Jiqiu Wen ◽  
Mariam Priya Alexander ◽  
Francis K. Buadi ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Light Chain ◽  
Mayo Clinic ◽  
Immunoglobulin Light Chain ◽  
Long Term Outcomes ◽  
Light Chain Amyloidosis ◽  
Immunoglobulin Light Chain Amyloidosis

Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic experience

2015 ◽  
Vol 15 ◽  
pp. S51 ◽  
Author(s):  
Taxiarchis V. Kourelis ◽  
Francis K. Buadi ◽  
Shaji K. Kumar ◽  
Morie A. Gertz ◽  
Martha Q. Lacy ◽  
...  
Keyword(s):  
Light Chain ◽  
Mayo Clinic ◽  
Immunoglobulin Light Chain ◽  
Light Chain Amyloidosis ◽  
Clinic Experience ◽  
Immunoglobulin Light Chain Amyloidosis

Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study

2015 ◽  
Vol 2 (6) ◽  
pp. e241-e250 ◽  
Author(s):  
Shameem Mahmood ◽  
Frank Bridoux ◽  
Christopher P Venner ◽  
Sajitha Sachchithanantham ◽  
Janet A Gilbertson ◽  
...  
Keyword(s):  
Natural History ◽  
Observational Study ◽  
Light Chain ◽  
Immunoglobulin Light Chain ◽  
Light Chain Amyloidosis ◽  
Immunoglobulin Light Chain Amyloidosis

scholarly journals Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis

Haematologica ◽  
2008 ◽  
Vol 93 (9) ◽  
pp. 1402-1406 ◽  
Author(s):  
M. A. Gertz ◽  
M. Q. Lacy ◽  
J. A. Lust ◽  
P. R. Greipp ◽  
T. E. Witzig ◽  
...  
Keyword(s):  
Light Chain ◽  
Immunoglobulin Light Chain ◽  
Light Chain Amyloidosis ◽  
Immunoglobulin Light Chain Amyloidosis

Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light chain amyloidosis

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 8559-8559
Author(s):  
M. A. Gertz ◽  
M. Q. Lacy ◽  
J. Lust ◽  
P. R. Greipp ◽  
T. E. Witzig ◽  
...  
Keyword(s):  
Light Chain ◽  
Immunoglobulin Light Chain ◽  
Light Chain Amyloidosis ◽  
Immunoglobulin Light Chain Amyloidosis

scholarly journals Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Linchun Xu ◽  
Yongzhong Su
Keyword(s):  
Plasma Cell ◽  
Light Chain ◽  
Amyloid Fibril ◽  
Treatment Modalities ◽  
Driver Gene ◽  
Immunoglobulin Light Chain ◽  
Disease Evolution ◽  
Genetic Aberrations ◽  
Light Chain Amyloidosis ◽  
Immunoglobulin Light Chain Amyloidosis

AbstractImmunoglobulin light chain amyloidosis (AL) is an indolent plasma cell disorder characterized by free immunoglobulin light chain (FLC) misfolding and amyloid fibril deposition. The cytogenetic pattern of AL shows profound similarity with that of other plasma cell disorders but harbors distinct features. AL can be classified into two primary subtypes: non-hyperdiploidy and hyperdiploidy. Non-hyperdiploidy usually involves immunoglobulin heavy chain translocations, and t(11;14) is the hallmark of this disease. T(11;14) is associated with low plasma cell count but high FLC level and displays distinct response outcomes to different treatment modalities. Hyperdiploidy is associated with plasmacytosis and subclone formation, and it generally confers a neutral or inferior prognostic outcome. Other chromosome abnormalities and driver gene mutations are considered as secondary cytogenetic aberrations that occur during disease evolution. These genetic aberrations contribute to the proliferation of plasma cells, which secrete excess FLC for amyloid deposition. Other genetic factors, such as specific usage of immunoglobulin light chain germline genes and light chain somatic mutations, also play an essential role in amyloid fibril deposition in AL. This paper will propose a framework of AL classification based on genetic aberrations and discuss the amyloid formation of AL from a genetic aspect.

Sign in / Sign up

Export Citation Format

Share Document